Difference between revisions of "Busulfan (Myleran)"
Jump to navigation
Jump to search
| Line 18: | Line 18: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/09386slr023_myleran_lbl.pdf Busulfan (Myleran) package insert]<ref name="insert"> | + | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/09386slr023_myleran_lbl.pdf Busulfan (Myleran) package insert]<ref name="insert"></ref> |
*[http://chemocare.com/chemotherapy/drug-info/busulfan.aspx Busulfan (Myleran) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/busulfan.aspx Busulfan (Myleran) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/busulfan.aspx Busulfan (Myleran) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/busulfan.aspx Busulfan (Myleran) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/busulfan-patient-drug-information Busulfan (Myleran) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/busulfan-patient-drug-information Busulfan (Myleran) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/busulfan-patient-drug-information Busulfan (Myleran) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/busulfan-patient-drug-information Busulfan (Myleran) patient drug information (UpToDate)]</ref> | ||
Revision as of 10:19, 4 April 2021
General information
Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.[1][2][3][4]
Route: IV, PO
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute myeloid leukemia
- Acute promyelocytic leukemia
- Chronic lymphocytic leukemia
- Chronic myelogenous leukemia
- CNS lymphoma
- Ewing sarcoma
Diseases for which it was used
Patient drug information
- Busulfan (Myleran) package insert[1]
- Busulfan (Myleran) patient drug information (Chemocare)[5]
- Busulfan (Myleran) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 6/26/1954: Initial FDA approval
- 1/23/2003: (earliest label available at Drugs@FDA) indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia.
Also known as
- Brand names: Busulfex, Myleran
References
- ↑ 1.0 1.1 1.2 Busulfan (Myleran) package insert
- ↑ Busulfan (Myleran) package insert (locally hosted backup)
- ↑ Busulfan (Busulfex) package insert
- ↑ Busulfan (Busulfex) package insert (locally hosted backup)
- ↑ Busulfan (Myleran) patient drug information (Chemocare)
- ↑ Busulfan (Myleran) patient drug information (UpToDate)
Categories:
- Drugs
- Oral medications
- Intravenous medications
- Alkylating agents
- Irritant
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- Chronic lymphocytic leukemia medications
- Chronic myelogenous leukemia medications
- CNS lymphoma medications
- Ewing sarcoma medications
- Multiple myeloma medications
- FDA approved in 1954